Fortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022
03 mars 2022 08h00 HE
|
Fortress Biotech, Inc.
MIAMI, March 03, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing...
Fortress Biotech to Participate in the 2nd Annual Winter Wonderland Best Ideas Virtual Investor Conference
07 févr. 2022 08h30 HE
|
Fortress Biotech, Inc.
MIAMI, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or...
Fortress Biotech to Participate in the H.C. Wainwright BioConnect Virtual Conference
06 janv. 2022 08h30 HE
|
Fortress Biotech, Inc.
MIAMI, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or...
Fortress Biotech to Ring Nasdaq Stock Market Closing Bell on December 21
21 déc. 2021 09h00 HE
|
Fortress Biotech, Inc.
NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or...
Fortress Biotech Announces Initiation of Phase 2 Clinical Trial of Triplex for Adults Co-Infected with HIV and CMV
16 déc. 2021 08h30 HE
|
Fortress Biotech, Inc.
Helocyte, Inc., a partner company of Fortress Biotech, is developing Triplex for the treatment of cytomegalovirus Clinical trial will evaluate whether Triplex, which was developed by City of Hope,...
Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce the Initiation of Rolling Submission of a New Drug Application for CUTX-101, Copper Histidinate, for Treatment of Menkes Disease
07 déc. 2021 08h00 HE
|
Fortress Biotech, Inc.
NEW YORK and SOLANA BEACH, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Cyprium Therapeutics, Inc. (“Cyprium”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) partner company, with support from...
Fortress Biotech Reports Record Third Quarter 2021 Financial Results and Recent Corporate Highlights
15 nov. 2021 16h01 HE
|
Fortress Biotech, Inc.
Net revenue for third quarter of 2021 increased 123% year-over-year to $21.1 million, a quarterly record Journey Medical Corporation, a Fortress partner company, launched its $35.2 million initial...
Fortress Biotech to Participate in Dawson James Securities’ 6th Annual Small Cap Growth Conference
18 oct. 2021 08h30 HE
|
Fortress Biotech, Inc.
NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or...
Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented at 2021 American Academy of Pediatrics National Conference & Exhibition
08 oct. 2021 08h00 HE
|
Fortress Biotech, Inc.
Cyprium Therapeutics, a partner company of Fortress Biotech, is developing CUTX-101 for the treatment of Menkes disease Overall survival significantly improved in patients treated with CUTX-101 ...
Fortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AstraZeneca
06 oct. 2021 08h00 HE
|
Fortress Biotech, Inc.
Triggers upfront payment of approximately $150 million to Caelum shareholders, of which approximately $64 million is payable to Fortress Biotech1 NEW YORK and BORDENTOWN, N.J., Oct. 06, 2021 ...